Polyglutamine misfolding in yeast: Toxic and protective aggregation

Prion

Volumn 5, Issue 4, 2011, Pages 285-290

  Duennwald, Martin L ^a  

^a BOSTON BIOMEDICAL RESEARCH INSTITUTE   (United States)

Author keywords

Aggresome; Huntington disease; Neurodegeneration; Polyglutamine proteins; Yeast models

Indexed keywords

POLYGLUTAMINE;

CONCEPTUAL FRAMEWORK; EXPERIMENTAL DESIGN; HUMAN; NONHUMAN; PRION; PROTEIN AGGREGATION; PROTEIN FOLDING; REVIEW; SACCHAROMYCES CEREVISIAE; TISSUE CULTURE; WORM; YEAST;

ANIMALS; HUMANS; PEPTIDES; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES; SACCHAROMYCES CEREVISIAE;

EID: 83755183685     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.5.4.18071     Document Type: Review

References (74)

1. Soto C, Estrada LD. Protein misfolding and neurodegeneration. Arch Neurol 2008; 65:184-9. (Pubitemid 351240778)
2. Carrell RW, Lomas DA. Conformational disease. Lancet 1997; 350:134-8. (Pubitemid 27313650)
3. Forman MS, Trojanowski JQ, Lee VM. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat Med 2004; 10:1055-63. (Pubitemid 39424865)
4. Fandrich M. On the structural definition of amyloid fibrils and other polypeptide aggregates. Cell Mol Life Sci 2007; 64:2066-78. (Pubitemid 350092423)
5. Nelson R, Eisenberg D. Structural models of amyloid-like fibrils. Adv Protein Chem 2006; 73:235-82. (Pubitemid 44960406)
6. Dobson CM. The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci 2001; 356:133-45. (Pubitemid 32241461)
7. Wolfe KJ, Cyr DM. Amyloid in neurodegenerative diseases: Friend or foe? Semin Cell Dev Biol.
8. Caughey B, Lansbury PT. Protofibrils, pores, fibrils and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26:267-98. (Pubitemid 37064935)
9. Barten DM, Albright CF. Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 2008; 37:171-86.
10. Citron M. Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9:387-98.
11. De Lorenzi E, Giorgetti S, Grossi S, Merlini G, Caccialanza G, Bellotti V. Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". Curr Med Chem 2004; 11:1065-84. (Pubitemid 38425931)
12. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300:486-9. (Pubitemid 36444329)
13. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 2004; 11:213-28. (Pubitemid 38689025)
14. Glabe CG. Structural classification of toxic amyloid oligomers. J Biol Chem 2008; 283:29639-43.
15. Shorter J, Lindquist S. Prions as adaptive conduits of memory and inheritance. Nat Rev Genet 2005; 6:435-50. (Pubitemid 40733889)
16. Epstein EA, Chapman MR. Polymerizing the fibre between bacteria and host cells: the biogenesis of functional amyloid fibres. Cell Microbiol 2008; 10:1413-20. (Pubitemid 351837262)
17. Si K, Choi YB, White-Grindley E, Majumdar A, Kandel ER. Aplysia CPEB can form prion-like multimers in sensory neurons that contribute to long-term facilitation. Cell 140:421-35.
18. Fowler DM, Koulov AV, Alory-Jost C, Marks MS, Balch WE, Kelly JW. Functional amyloid formation within mammalian tissue. PLoS Biol 2006; 4:6.
19. Maji SK, Perrin MH, Sawaya MR, Jessberger S, Vadodaria K, Rissman RA, et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 2009; 325:328-32.
20. True HL, Berlin I, Lindquist SL. Epigenetic regulation of translation reveals hidden genetic variation to produce complex traits. Nature 2004; 431:184-7. (Pubitemid 39243470)
21. True HL, Lindquist SL. A yeast prion provides a mechanism for genetic variation and phenotypic diversity. Nature 2000; 407:477-83.
22. Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007; 30:575-621. (Pubitemid 47218768)
23. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000; 23:217-47. (Pubitemid 30350043)
24. Zoghbi HY, Orr HT. Pathogenic mechanisms of a polyglutamine mediated neurodegenerative disease: SCA1. J Biol Chem 2008.
25. Giorgini F, Muchowski PJ. Screening for genetic modifiers of amyloid toxicity in yeast. Methods Enzymol 2006; 412:201-22. (Pubitemid 44548582)
26. Gitler AD. Beer and bread to brains and beyond: can yeast cells teach us about neurodegenerative disease? Neurosignals 2008; 16:52-62. (Pubitemid 350308321)
27. Miller-Fleming L, Giorgini F, Outeiro TF. Yeast as a model for studying human neurodegenerative disorders. Biotechnol J 2008; 3:325-38.
28. van Ham TJ, Breitling R, Swertz MA, Nollen EA. Neurodegenerative diseases: Lessons from genome-wide screens in small model organisms. EMBO Mol Med 2009; 1:360-70.
29. Outeiro TF, Lindquist S. Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 2003; 302:1772-5. (Pubitemid 37505742)
30. Johnson BS, McCaffery JM, Lindquist S, Gitler AD. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci USA 2008; 105:6439-44. (Pubitemid 351758364)
31. Konopka CA, Locke MN, Gallagher PS, Pham N, Hart MP, Walker CJ, et al. A yeast model for polyalanine-expansion aggregation and toxicity. Mol Biol Cell 22:1971-84.
32. Fushimi K, Long C, Jayaram N, Chen X, Li L, Wu JY. Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. Protein Cell 2:141-9.
33. Ju S, Tardiff DF, Han H, Divya K, Zhong Q, Maquat LE, et al. A yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol 9:1001052.
34. Sun Z, Diaz Z, Fang X, Hart MP, Chesi A, Shorter J, et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol 9:1000614.
35. Duennwald ML, Jagadish S, Giorgini F, Muchowski PJ, Lindquist S. A network of protein interactions determines polyglutamine toxicity. Proc Natl Acad Sci USA 2006; 103:11051-6. (Pubitemid 44148416)
36. Duennwald ML, Jagadish S, Muchowski PJ, Lindquist S. Flanking sequences profoundly alter polyglutamine toxicity in yeast. Proc Natl Acad Sci USA 2006; 103:11045-50. (Pubitemid 44148415)
37. Krobitsch S, Lindquist S. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad Sci USA 2000; 97:1589-94. (Pubitemid 30118486)
38. Meriin AB, Mabuchi K, Gabai VL, Yaglom JA, Kazantsev A, Sherman MY. Intracellular aggregation of polypeptides with expanded polyglutamine domain is stimulated by stress-activated kinase MEKK1. J Cell Biol 2001; 153:851-64. (Pubitemid 34286115)
39. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl FU. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc Natl Acad Sci USA 2000; 97:7841-6. (Pubitemid 30460735)
40. Giorgini F, Guidetti P, Nguyen Q, Bennett SC, Muchowski PJ. A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet 2005; 37:526-31. (Pubitemid 40617282)
41. Meriin AB, Zhang X, Alexandrov IM, Salnikova AB, Ter-Avanesian MD, Chernoff YO, et al. Endocytosis machinery is involved in aggregation of proteins with expanded polyglutamine domains. FASEB J 2007; 21:1915-25. (Pubitemid 46855636)
42. Duennwald ML, Lindquist S. Impaired ERAD and ER stress are early and specific events in polyglutamine toxicity. Genes Dev 2008; 22:3308-19.
43. Osherovich LZ, Weissman JS. Multiple Gln/Asn-rich prion domains confer susceptibility to induction of the yeast [PSI(+)] prion. Cell 2001; 106:183-94. (Pubitemid 32772629)
44. Meriin AB, Zhang X, He X, Newnam GP, Chernoff YO, Sherman MY. Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a prion-like protein Rnq1. J Cell Biol 2002; 157:997-1004. (Pubitemid 34839774)
45. Gokhale KC, Newnam GP, Sherman MY, Chernoff YO. Modulation of prion-dependent polyglutamine aggregation and toxicity by chaperone proteins in the yeast model. J Biol Chem 2005; 280:22809-18. (Pubitemid 40853187)
46. Greiner ER, Yang XW. Huntington's disease: flipping a switch on huntingtin. Nat Chem Biol 7:412-4.
47. Liebman SW, Meredith SC. Protein folding: sticky N17 speeds huntingtin pile-up. Nat Chem Biol 6:7-8.
48. Robertson AL, Bottomley SP. Towards the treatment of polyglutamine diseases: the modulatory role of protein context. Curr Med Chem 17:3058-68.
49. Dehay B, Bertolotti A. Critical role of the proline-rich region in Huntingtin for aggregation and cytotoxicity in yeast. J Biol Chem 2006; 281:35608-15. (Pubitemid 46041291)
50. Wang Y, Meriin AB, Zaarur N, Romanova NV, Chernoff YO, Costello CE, et al. Abnormal proteins can form aggresome in yeast: aggresome-targeting signals and components of the machinery. FASEB J 2009; 23:451-63.
51. Wang CE, Tydlacka S, Orr AL, Yang SH, Graham RK, Hayden MR, et al. Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease. Hum Mol Genet 2008; 17:2738-51.
52. Kopito RR. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol 2000; 10:524-30.
53. Olzmann JA, Li L, Chin LS. Aggresome formation and neurodegenerative diseases: therapeutic implications. Curr Med Chem 2008; 15:47-60. (Pubitemid 351234627)
54. Bar-Nun S. The role of p97/Cdc48p in endoplasmic reticulum-associated degradation: from the immune system to yeast. Curr Top Microbiol Immunol 2005; 300:95-125. (Pubitemid 43057938)
55. Khoshnan A, Ko J, Patterson PH. Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci USA 2002; 99:1002-7. (Pubitemid 34106625)
56. Southwell AL, Khoshnan A, Dunn DE, Bugg CW, Lo DC, Patterson PH. Intrabodies binding the proline- rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci 2008; 28:9013-20.
57. Bhattacharyya A, Thakur AK, Chellgren VM, Thiagarajan G, Williams AD, Chellgren BW, et al. Oligoproline effects on polyglutamine conformation and aggregation. J Mol Biol 2006; 355:524-35. (Pubitemid 41785754)
58. Brignull HR, Morley JF, Morimoto RI. The stress of misfolded proteins: C. elegans models for neurodegenerative disease and aging. Adv Exp Med Biol 2007; 594:167-89.
59. Voisine C, Hart AC. Caenorhabditis elegans as a model system for triplet repeat diseases. Methods Mol Biol 2004; 277:141-60.
60. Driscoll M, Gerstbrein B. Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat Rev Genet 2003; 4:181-94. (Pubitemid 36267889)
61. Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci USA 2002; 99:10417-22.
62. Steinkraus KA, Smith ED, Davis C, Carr D, Pendergrass WR, Sutphin GL, et al. Dietary restriction suppresses proteotoxicity and enhances longevity by an hsf-1-dependent mechanism in Caenorhabditis elegans. Aging Cell 2008; 7:394-404. (Pubitemid 351663908)
63. Faber PW, Voisine C, King DC, Bates EA, Hart AC. Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc Natl Acad Sci USA 2002; 99:17131-6. (Pubitemid 36034110)
64. Shulman JM, Shulman LM, Weiner WJ, Feany MB. From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease. Curr Opin Neurol 2003; 16:443-9. (Pubitemid 36951819)
65. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, Martinez P, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 2000; 408:101-6.
66. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, Purcell J, et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000; 9:13-25. (Pubitemid 30145284)
67. Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, Kanuka H, et al. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002; 35:855-64.
68. Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, Pittman RN, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998; 93:939-49. (Pubitemid 28280788)
69. Aiken CT, Tobin AJ, Schweitzer ES. A cell-based screen for drugs to treat Huntington's disease. Neurobiol Dis 2004; 16:546-55. (Pubitemid 38942987)
70. Apostol BL, Kazantsev A, Raffioni S, Illes K, Pallos J, Bodai L, et al. A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila. Proc Natl Acad Sci USA 2003; 100:5950-5. (Pubitemid 36576913)
71. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, et al. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 2001; 12:1393-407. (Pubitemid 33044419)
72. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S, et al. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum Mol Genet 2003; 12:749-57. (Pubitemid 36416961)
73. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004; 431:805-10. (Pubitemid 39434070)
74. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, Hyman BT, et al. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci USA 2006; 103:4246-51.